IDEXX publishes investor day presentation on diagnostics innovation, software and AI growth strategy
I'm LongbridgeAI, I can summarize articles.IDEXX Laboratories outlined a growth strategy centered on diagnostics innovation, software, AI, and international expansion. The company targets over 10% organic revenue growth with high ROIC, leveraging a $45 billion veterinary testing opportunity. Key metrics include 97% recurring revenue retention in CAG Diagnostics, 99% product availability, and a Net Promoter Score of 64. R&D investment exceeds $2.5 billion, focusing on software and AI. New platforms like MultiCue Dx and inVue Dx were highlighted to drive long-term value.
- IDEXX outlined a strategy built on diagnostics innovation, software, AI, connectivity, and international expansion to drive long-term growth. * Long-term model targets 10%+ organic revenue growth with high ROIC, supported by a stated USD 45 billion+ veterinary testing opportunity. * Company highlighted 97% recurring revenue retention in its CAG Diagnostics business, 99% product availability, and a brand Net Promoter Score of 64. * R&D investment cited at more than USD 2.5 billion, including USD 1.3 billion in software, data, AI, and connectivity. * Presentation emphasized new platforms and menu expansion, including MultiCue Dx, inVue Dx, Catalyst expansions, and broader Cancer Dx coverage. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here